CD19 is a protein found on the surface of B cells — a type of white blood cell that helps the body fight infections by producing antibodies (proteins the immune system uses to recognize and attack germs). CD19 is one of the most reliable markers of B cells: it appears very early as a B cell develops in the bone marrow and remains on the cell’s surface throughout most of its life. Because of this, pathologists use CD19 to identify B cells in tissue samples and to diagnose cancers that arise from B cells, including most types of B-cell lymphoma and certain leukemias. CD19 is also one of the most important treatment targets in modern cancer therapy — several powerful drugs and cell-based treatments are designed specifically to recognize and destroy CD19-positive cells.
Why do pathologists test for CD19?
CD19 is tested for two main reasons:
- To identify B cells in a tissue sample. Because CD19 is present on virtually all B cells, it is one of the most useful markers for confirming that the cells in question are B cells. This is essential for diagnosing and classifying B-cell lymphomas and leukemias — cancers of the immune system that arise from B cells.
- To identify candidates for CD19-targeted therapy. CD19 is the molecular target of several modern cancer treatments, including CAR-T cell therapy — a treatment in which a patient’s own immune cells (T cells) are modified in the laboratory to recognize and attack CD19-positive cells. Identifying CD19 expression on a tumor confirms that these therapies could be used.
How is CD19 tested?
CD19 can be detected using two laboratory techniques, often used together:
- Immunohistochemistry (IHC) — performed on a thin slice of tissue placed on a glass slide. An antibody (a protein designed to attach specifically to CD19) is applied to the tissue, producing a color change visible under the microscope wherever CD19 is present.
- Flow cytometry — a laboratory test that uses a special machine to examine individual cells one by one in a sample of blood, bone marrow, or lymph node tissue. The machine can rapidly identify and count cells carrying CD19 and other markers, providing detailed information about the cell types present. Flow cytometry is especially useful for diagnosing and monitoring blood cancers.
How results are reported
CD19 results are reported as positive or negative:
- Positive (reactive) — CD19 protein is detected on the cells. In the context of a suspected B-cell lymphoma or leukemia, a positive result confirms that the cancer cells are B cells. This finding is also relevant for treatment selection, since CD19-positive cancers may be candidates for CD19-targeted therapy.
- Negative (non-reactive) — CD19 protein is not detected. In a suspected lymphoma, a negative result helps rule out a B-cell origin and points the pathologist toward other diagnoses such as a T-cell lymphoma or a non-lymphoid cancer. A negative result after previous CD19-targeted treatment may also indicate that the cancer has changed and may no longer respond to that specific therapy.
Which cancers are typically CD19 positive?
Most cancers arising from B cells are CD19 positive. The most common include:
- Chronic lymphocytic leukemia (CLL) — a slow-growing cancer of mature B cells most often found in adults.
- Small lymphocytic lymphoma (SLL) — closely related to CLL, but the cancer cells are mainly found in lymph nodes rather than circulating in the blood.
- Follicular lymphoma — a slow-growing B-cell lymphoma that arises from cells in the germinal centers of lymph nodes (specialized regions where B cells normally develop).
- Diffuse large B-cell lymphoma (DLBCL) — the most common aggressive B-cell lymphoma; CD19 testing is essential because DLBCL is one of the cancers most commonly treated with CD19-targeted therapy.
- Mantle cell lymphoma — an aggressive B-cell lymphoma that often spreads widely at the time of diagnosis.
- B lymphoblastic leukemia (B-ALL) — an aggressive cancer arising from immature B cells, most common in children but also seen in adults. B-ALL is one of the cancers in which CD19-targeted CAR-T cell therapy was first approved.
What does CD19 mean for treatment?
For patients with certain B-cell cancers, CD19 has become one of the most important targets for cancer therapy. Several types of treatment specifically target CD19-positive cells, including:
- CAR-T cell therapy — a personalized treatment in which a patient’s own T cells (a type of immune cell) are removed from the blood, genetically modified in the laboratory to recognize CD19, and then returned to the body where they attack CD19-positive cancer cells. CAR-T cell therapies have produced lasting responses in some patients with previously treatment-resistant B-cell cancers.
- Bispecific antibodies — laboratory-made proteins designed to attach simultaneously to CD19 (on the cancer cell) and to a marker on healthy T cells, bringing the two together so the immune system can destroy the cancer cell.
- Antibody-drug conjugates — antibodies that recognize CD19 with a powerful cancer-killing drug attached. The antibody delivers the drug directly to CD19-positive cells.
Confirmation of CD19 expression on the cancer cells is required before any of these treatments can be used. If CD19 is later lost — sometimes a way that cancers escape these therapies — additional testing and a change in treatment may be needed.
Questions to ask your doctor
- Was CD19 tested in my tumor or blood, and what was the result?
- Does my CD19 result confirm that my cancer is a B-cell type?
- Am I a candidate for CD19-targeted treatment such as CAR-T cell therapy?
Related articles on MyPathologyReport.com